Suboticanec K, Folnegovic-Smalc V, Korbal M, Mestrovic B, Buzina R
[DOI] [PubMed] [Google Scholar] 26.Blom-Hgestl I.K., Mala T., Kristinsson J.A., Brunborg C., Gulseth H.L., Eriksen E.F
This is one of the first papers that correctly elaborated on Metformins ability to lower blood glucose in patients with high blood sugar, while keeping those levels stable in patients with normal blood sugar levels
Psyllium : You know this oneit's the fiber in Metamucil that helps with, well, keeping things moving
This can make your subscription essentially free if you've got unused HSA or FSA funds sitting around
A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026